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Objectives: To compare the outcomes of transfemoral ACURATE neo (NEO) and
Sapien 3 (S3) patients in terms of device success and clinical safety outcomes using a
propensity score analysis.
Background: Differences in clinical outcomes between the latest-generation balloon-
expandable S3 and self-expanding NEO in a “real-world transfemoral TAVI popula-
tion” are still unclear.
Methods: We compared up to 6 months clinical outcomes using a propensity score
analysis (inverse probability of treatment weighting [IPTW]) to account for differ-
ences in baseline characteristics.
Results: A total of 345 patients underwent transfemoral transcatheter aortic valve
implantation (TAVI) with either NEO or S3 at two centers in the Netherlands. Com-
posite device success and early safety endpoints were comparable between NEO
and S3 (Device success: IPTW-adjusted OR: 0.35 [95% CI: 0.12–1.18], and early
safety: IPTW-adjusted OR: 0.51 [95% CI: 0.19–1.38]). Six-months mortality was 5.3
versus 3.6%, stroke was 2.8 versus 3.3%, and pacemaker rate was 6.1 versus 8.6%,
respectively with p = NS. Mean aortic gradient was lower in the NEO group (5.72
± 2.47 vs. 9.05 ± 3.48; p = <.001), with a comparable rate of moderate or severe
paravalvular leak (0 versus 2.1%; p = NS).
Conclusions: Device success and clinical safety outcomes were comparable for both
valves. Up to 6-months follow-up clinical outcomes and mortality rate remained
excellent. Mean aortic gradient was lower after ACURATE neo implantation.
Abbreviations: AS, aortic stenosis; NEO, ACURATE neo; NYHA, New York Heart Association; PPI, permanent pacemaker implantation; PVL, paravalvular leak; S3, Sapien 3; TAVI, transcatheter
aortic valve implantation; THVs, transcatheter heart valves; TIA, transient ischemic attack; VARC-2, Valve Academic Research Consortium-2.
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1 | INTRODUCTION
The transcatheter heart valves (THVs) used in transcatheter aortic
valve implantation (TAVI) are rapidly evolving and leading to an
improved safety profile and higher rates of clinical success in low to
high risk and inoperable patients with severe aortic stenosis.1 Over the
last decade, the deployment of THVs in TAVI is based mainly on two
technical concepts: the balloon-expandable and the self- expanding
approach. Both technologies have shown excellent clinical results.2 In
earlier-generation THVs, comparison of both techniques showed supe-
riority of balloon-expandable over self-expanding THVs.2 The rate of
device success of the self-expanding THVs was lower due to more
residual moderate or severe aortic regurgitation. Moreover, placement
of a new permanent pacemaker was more frequent in self-expanding
THVs. The development of new generation balloon-expandable
(Sapien 3 [S3], Edwards Lifesciences, Irvine, CA) and self-expanding
(e.g., ACURATE neo [NEO], Boston Scientific, Ecublens, Switzerland;
CoreValve Evolut R, Medtronic, Dublin, Ireland) THVs has taken place
to address limitations of earlier-generation devices and to improve
safety and clinical outcomes. With the increasing number of proce-
dures and expansion of TAVI into low risk and younger patients,
improving safety and clinical outcomes gain increasing relevance. For
these clinical improvements, strengths and limitations of different val-
ves need to be studied to enable a patient-tailored device selection.
Current results of single-arms registries of the S3 and NEO THV sug-
gest important advances for both valves with high rates of device success,
low rates of pacemaker implantation and low mortality.3-10 Several retro-
spective and prospective observational studies comparing both valves
have been published recently.11-16 However, these studies reported
inconsistent results, only short term outcomes up to 1 month, or only a
subgroup of TAVI patients were included. In the most recent randomized
SCOPE I trial, the NEO valve did not meet non-inferiority compared to S3
device in terms of early safety and clinical efficacy outcomes at 30 days.17
Currently, no data are available comparing the latest-generation
balloon-expandable S3 and self-expanding NEO in a “real-world trans-
femoral TAVI population”. The present study aims to elucidate causal
treatment effects and differences in clinical outcome of both devices
in terms of device success, 30-days and 6-months clinical outcome
after transfemoral TAVI using real-world observational TAVI data.
2 | METHODS
2.1 | Study design and patient population
Between March 2016 and November 2018, all consecutive patients
with symptomatic, severe aortic stenosis who underwent transfemoral
TAVI using S3 or NEO at two Dutch centers were included in this retro-
spective study. Patients with pre-existing aortic bioprostheses or bicus-
pid valve were excluded due to no occurrence in one of the groups.
Patients with missing baseline data necessary for the propensity score
were excluded. All TAVI candidates were discussed by the Heart Team
and consensus was achieved regarding the optimal therapeutic strategy.
The final decision on prosthesis type and size was left at the discretion
of the treating interventional cardiologist. This was mainly based on the
proper sizing between the available valve size of each valve type, the
aortic annulus size of the patient, local experience, and the extent of
aortic valve calcification. Table S1 provides a general overview of deter-
minant features for device selection. Statistical analysis using IPTW was
performed on this retrospective data to compensate for the lack of ran-
dom assignment of the valves and to be able to estimate the causal
treatment effects of both valves. The study complies with the Declara-
tion of Helsinki and was approved by the local ethics committee.
2.2 | Study devices and procedure
The balloon-expandable S3 is a trileaflet valve made of bovine pericar-
dial tissue, which is incorporated into a cobalt-chromium frame. An
external polyethylene terephthalate sealing cuff was complemented
to the inflow of the frame to reduce paravalvular leak (PVL). The S3 is
delivered with the Commander delivery system, 14 or 16 French
e-sheath and mandatory rapid ventricular pacing during implantation
and is available in the sizes 23-, 26-, and 29-mm.18
The self-expanding NEO is a supra-annular positioned tri-leaflet
valve made of a porcine pericardial tissue, which is incorporated into an
X-shaped nitinol frame. The inner and outer surface of the stent body is
covered by a pericardial sealing skirt. The NEO is delivered with the NEO
delivery system, 14 French iSleeve which can be implanted without rapid
ventricular pacing and is available in the sizes 23-, 25- and 27- mm.19
The transfemoral TAVI procedures were mainly performed under
conscious sedation or local anesthesia with fluoroscopic guidance for
prosthesis positioning and deployment. Accurate positioning and
function of the prosthesis and the patency of the coronary ostia were
ascertained by angiographic guidance. Finally, in case of significant
aortic regurgitation post-dilation or second valve implantation was
performed, at discretion of the operator.
2.3 | Echocardiographic and multislice computed
tomography evaluation
All patients underwent transthoracic echocardiogram and multislice
computed tomography. Transthoracic echocardiogram was performed
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before the procedure, at discharge, and at 6 months to evaluate val-
ve's function and degree of aortic regurgitation. Multislice computed
tomography was performed pre-procedural to evaluate the aortic
annulus measurements and aortic root dimensions and to determine
the eligibility of access site for the TAVI procedure.
2.4 | Study endpoints and follow-up definitions
The endpoints of this study were set according to the VARC-2
criteria.20 Outcomes were device success, early safety composite end-
point at 30 days and clinical complications at 6 months. Device suc-
cess is a composite endpoint of absence of peri-procedural mortality,
correct positioning of a single valve, mean aortic valve gradient
<20 mmHg and absence of moderate or severe PVL. Early safety com-
posite endpoint at 30 days includes mortality, any stroke, life-
threatening bleeding, acute kidney injury (stage 2 or higher), major
vascular complication, coronary artery obstruction requiring interven-
tion, and all valve-related dysfunction requiring repeat procedure.
Follow-up data were obtained using documentation of standard care
of outpatient visits. Information regarding survival status was
obtained by interrogation of the Dutch national institute of statistics.
2.5 | Statistical analysis
Continuous variables are expressed as means with the standard devia-
tion or as the median with the interquartile range depending on the
distribution, and categorical variables as counts and percentages. Con-
tinuous variables were compared using two-sample t-tests, when data
was normally distributed, or Mann–Whitney U test, when data was
not normally distributed. Categorical variables were compared using
Chi-square, for large-sized sample, or Fisher's Exact test, for small-
sized samples, as appropriate.
Because of the nonrandomized nature of this study, the inverse
probability of treatment weighting (IPTW) method using propensity
score was performed to reduce the imbalance in patient baseline char-
acteristics with the aim of minimizing the potential effect of selection
bias on the outcomes for comparing NEO and S3.21 The baseline fea-
tures used for the propensity score were: age, sex, body mass index,
logistic EuroSCORE I, New York Heart Association (NYHA) functional
class III/IV, diabetes mellitus, hypertension, hypercholesterolemia, glo-
merular filtration rate, peripheral artery disease (PAD), prior myocar-
dial infarction, coronary artery bypass grafting, left ventricular
ejection fraction <30%, prior stroke, prior transient ischemic attack
(TIA), prior coronary artery disease, chronic obstructive pulmonary
disease, porcelain aorta, atrial fibrillation/flutter, prior permanent
pacemaker, and moderate/severe mitral regurgitation. Standardized
mean differences (SMD) were calculated, and absolute SMD <0.1
were considered as a negligible difference between the means of the
two cohorts and thus sufficient bias reduction.22
IPTW uses the whole dataset but reweights individuals to
increase the weights of those who received unexpected exposures.
IPTW weights were stabilized and the weights under first and above
99th percentile were respectively set to the value of the first and
99th percentile to address extreme weights.23 The confidence interval
of IPTW was computed with robust standard errors.24 To estimate
the overall treatment effect and confidence limits, the odds ratio's for
clinical outcome, the mean aortic gradient, PVL, and NYHA class, and
time-to-event Kaplan–Meier for mortality were adjusted for IPTW.
Two-tailed p values <.05 were considered statistically significant. Data
were analyzed using the R Statistics software version 3.5.1 and the
packages “MatchIt” and “Survey.”
3 | RESULTS
3.1 | Baseline characteristics
Overall, 345 patients were treated with transfemoral TAVI with either
S3 or NEO. In total, 37 patients were excluded due to valve-in-valve
procedures (n = 8), bicuspid aortic valve (n = 18) and due to missing
data in variables required for the propensity score (n = 11). Of the
remaining 308 patients, 230 received the balloon-expandable valve
S3 and 78 patients the self-expanding valve NEO (Figure 1).
The IPTW-adjusted groups were well balanced in terms of base-
line characteristics (Table 1), except for gender, PAD and left ventricle
ejection fraction (LVEF) <30%. Patients treated with NEO were more
frequently female compared to patients treated with S3 (59.6
vs. 53.0%; SMD = 0.133). In the NEO group the incidence of patients
with PAD and LVEF <30% was significantly lower compared with the
S3 group (9.7 vs. 14.5%; SMD = 0.148, and 5.2 vs. 0%; SMD = 0.331,
respectively). Approximately half of the patients in both groups were
severely symptomatic (NYHA class III/IV). Most of the patients had an
intermediate surgical risk as predicted by the Logistic EuroSCORE I
(14.6 ± 10.1 in the S3 group and 14.9 ± 9.4 in the NEO group).
3.2 | Procedural features
An overview of the procedural features is shown in Table 2. Pre- and
post-dilation were performed significantly more frequent in NEO; for
pre-dilation (NEO 97.4% vs. S3 65.2%; IPTW-adjusted OR: 14.6 [95%
CI: 2.9–73.7]; p = .001), for post-dilation (NEO 35.9% vs. S3 13.5%;
IPTW-adjusted OR: 5.25 [95% CI: 2.69–10.24]; p = <.001). There were
no significant differences in fluoroscopy time, contrast volume used
and intervention time between both valves. Rates of conversion to car-
diac surgery during the procedure were low and similar for both valves.
3.3 | Device success
Table 2 shows the rate of device success for both THVs (Table 2).
There was no significant difference in device success between both
groups (NEO 89.3% vs. S3 94.6%; IPTW-adjusted OR: 0.35 [95%
CI: 0.12–1.18]; p = .061), with NEO's higher rate of second valve
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implantation as main difference between both valves. Peri-
procedural mortality rate was 2.6% for NEO and 1.3% for S3
(IPTW-adjusted OR: 3.34 [95% CI: 0.42–26.46]; p = .255). There
was no significant difference in rate of post-procedural mean gradi-
ent ≥20 mmHg and rate of moderate or severe PVL between both
valves.
F IGURE 1 Study flowchart
TABLE 1 Baseline patient characteristics of the unmatched and IPTW-adjusted cohort
Variable
Unmatched IPTW-adjusted
NEO (n = 78) S3 (n = 230) SMD NEO (n = 69.89) S3 (n = 229.74) SMD
Age (years) 81.2 ± 5.6 80.2 ± 7.2 0.150 80.8 ± 5.8 80.4 ± 7.1 0.055
Female (%) 58 (74.4) 104 (45.2) 0.622 41.6 (59.6) 121.7 (53.0) 0.133
BMI (kg/m2) 26.3 ± 4.8 26.5 ± 5.2 0.020 26.7 ± 5.2 26.3 ± 5.3 0.064
Logistic EuroSCORE I (%) 13.4 ± 7.6 14.8 ± 10.6 0.151 14.9 ± 9.4 14.6 ± 10.1 0.026
NYHA class III/IV (%) 43 (55.1) 100 (43.5) 0.235 34.4 (49.2) 106.4 (46.3) 0.057
Diabetes mellitus (%) 24 (30.8) 60 (26.1) 0.104 22.1 (31.6) 63.2 (27.5) 0.089
Hypertension (%) 52 (66.7) 151 (65.7) 0.021 44.3 (63.4) 150.3 (65.4) 0.042
Hypercholesterolemia (%) 44 (56.4) 127 (55.2) 0.024 41.1 (58.8) 129.1 (56.2) 0.053
eGFR ml/min/1.73 m2 61 ± 19 61 ± 20) 0.020 61 ± 19 61 ± 20 0.010
Stroke (%) 8 (10.3) 18 (7.8) 0.085 6.8 (9.7) 19.7 (8.6) 0.041
TIA (%) 6 (7.7) 36 (15.7) 0.250 9.7 (13.9) 31.6 (13.8) 0.005
Peripheral artery disease (%) 5 (6.4) 40 (17.4) 0.344 6.8 (9.7) 33.3 (14.5) 0.148
Prior myocardial infarction (%) 10 (12.8) 42 (18.3) 0.151 11.2 (16.0) 39.2 (17.1) 0.030
Coronary artery disease (%) 39 (50.0) 95 (41.3) 0.175 30.8 (44.1) 99.7 (43.4) 0.014
Chronic pulmonary disease (%) 12 (15.4) 44 (19.1) 0.099 13.4 (19.2) 42.7 (18.6) 0.015
Porcelain aorta (%) 7 (9.0) 10 (4.3) 0.186 4.0 (5.7) 12.1 (5.3) 0.018
Atrial fibrillation (%) 20 (25.6) 83 (36.1) 0.228 23.4 (33.5) 77.4 (33.7) 0.005
Permanent pacemaker (%) 5 (6.4) 25 (10.9) 0.159 7.7 (11.0) 22.9 (10.0) 0.032
LVEF<30% (%) 0 (0.0) 16 (7.0) 0.387 0.0 (0.0) 11.9 (5.2) 0.331
Moderate or severe MR (%) 10 (12.8) 42 (18.3) 0.151 10.5 (15.1) 38.7 (16.9) 0.049
Note: Values are expressed as n (%) or mean ± SD.
Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate; IPTW, inverse probability of treatment weighting; LVEF, left ventricular
ejection fraction; MR, mitral regurgitation; NYHA, New York Heart Association; SMD, standardized mean differences; TIA, transient ischemic attack.
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TABLE 2 Periprocedural and 30-days outcome
Periprocedural
Crude (unadjusted) IPTW-adjusted
NEO (n = 78) S3 (n = 230) p-value NEO (n = 69.89) S3 (n = 229.74) p-value
Fluoroscopy time (min) 17 (13–20) 15 (12–19) .204 16 (12–20) 15 (12–19) .626
Contrast volume (ml) 134 ± 32 118 ± 29 <.001 131 ± 32 119 ± 29 .007
Intervention time (min) 79 (68–97) 76 (66–92) .248 79 (67–101) 76 (66–93) .336
Valvesize
20 0 (0) 1 (0.4)
23 (small) 7 (9.0) 37 (16.1)
25 (medium) 38 (48.7) 0 (0)
26 0 (0) 115 (50)
27 (large) 33 (42.3) 0 (0)
29 0 (0) 77 (33.5)
IPTW-adjusted OR
General anesthesia (%) 0/78 (0.0) 8/230 (3.5) .209 0.99 (0.74–1.33) .957
Pre-dilation (%) 76/78 (97.4) 150/230 (65.2) <.001 14.6 (2.89–73.68) .001
Post-dilation (%) 28/78 (35.9) 31/230 (13.5) <.001 5.25 (2.69–10.24) <.001
Conversion to cardiac surgery (%) 2/78 (2.6) 1/230 (0.4) .159 4.32 (0.38–48.72) .238
Device successa (%)
Device successa 67/75 (89.3) 212/224 (94.6) 0.35 (0.12–1.05) .061
Periprocedural mortality (%) 2/78 (2.6) 3/230 (1.3) 3.34 (0.42–26.46) .255
Valve malpositioning (%) 2/78 (2.6) 0/230 (0.0) — —
Single valve implantation (%) 73/78 (93.6) 227/230 (98.7) 0.17(0.03–0.84) .031
Prosthetic valve mean
gradient <20 mmHg (%)




1/73 (1.4) 3/225 (1.3) 2.84 (0.29–28.04) .371
30-days outcome
Early safety at 30 days (%) 66/76 (86.8) 209/226 (92.5) 0.53 (0.20–1.43) .214
Mortality (%) 3/78 (3.8) 4/230 (1.7) 3.54 (0.63–19.84) .152
Stroke (%) 1/73 (1.4) 5/224 (2.2) 0.40 (0.04–3.50) .406
Life-threatening bleeding (%) 5/76 (6.6) 10/225 (4.4) 1.48 (0.39–5.53) .563
Acute kidney injury stage 2
or 3 (%)
0/77 (0) 0/229 (0) —
Major vascular complication
(%)








0/72 (0) 0/222 (0) —
Pacemaker implantationb 3/68 (4.4) 14/197 (7.1) 0.55 (0.14–2.09) .380
Note: Values are expressed as n (%), mean ± SD or median (IQR).
Abbreviation: IPTW, inverse probability of treatment weighting.
aDevice success is a composite of absence of periprocedural mortality, correct positioning of a single valve, mean aortic valve gradient <20 mmHg and
absence of moderate or severe prosthetic valve regurgitation.
bPatients with pacemaker at baseline were excluded.
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3.4 | Thirty-days outcome
The early safety composite endpoint at 30 days was comparable in
both groups (NEO 86.5% vs. S3 92.5%; IPTW-adjusted OR: 0.51 [95%
CI: 0.19–1.38]; p = .189) (Table 2). Comparing the individual contribu-
tors to the composite endpoint showed no statistically significant dif-
ferences. There were no cases of acute kidney injury stage 2 or 3 in
both groups. Rate of new permanent pacemaker implantation (PPI)
was comparable in both groups (NEO 4.4% vs. S3 7.1%; IPTW-
adjusted OR: 0.55 [95% CI: 0.14–2.09]; p = .380).
3.5 | 6 months outcome
At 6 months, there were no significant differences in clinical outcomes
(Figures 2 and 3). Six-months mortality was 5.3 vs. 3.6%, stroke was
2.8 vs. 3.3%, and pacemaker rate was 6.1 vs. 8.6% for NEO vs. S3
respectively with p = NS). Cardiovascular related deaths were also
comparable between both valves (NEO 3.9% vs. S3 2.3%, p = NS) with
annulus rupture being the most important reason of death peri-
procedural (1 case in NEO versus 2 cases in S3). Generally, symptom-
atic improvement after TAVI was similar in both valve types
(Figure 4).
Echocardiographic data regarding the valve function up to
6 months is shown in Figure 5. The mean aortic gradient remained sig-
nificantly lower in the NEO compared to S3 at 6 months of follow-up
(5.72 ± 2.47 vs. 9.05 ± 3.48; p = <.001; Figure 5a).
At discharge there were significantly more patients with mild PVL
in the NEO group (51.6 vs. 22%; p = <.001) (Figure 5b). However, at
6 months the rate of mild PVL in the NEO group was reduced from
51.6 to 33%, which was not different from the patients receiving a S3
valve (29.9%; p = .887). There were no cases of central regurgitation.
4 | DISCUSSION
To our knowledge, this is the first propensity score adjusted compari-
son of clinical outcomes up to 6-months in a real-world population of
patients that underwent a transfemoral TAVI with either a NEO or S3
valve. Main findings of this study were as follows: (a) PPI rate was low
for both NEO and S3, (b) device success and outcomes regarding the
early safety composite endpoint within 30 days were comparable
between both valve types, (c) the post-procedural mean aortic valve
gradient is significantly lower within the NEO group, (d) and overall
clinical outcomes at 6 months were comparable between both valve
types.
4.1 | New permanent pacemaker implantation
The rate of new PPI in our study was similar for both valves, neverthe-
less impressively low, especially for the self-expanding NEO. In
earlier-generation self-expanding THVs, new PPI rates ranged
between 21–45%.2,25,26 Although the trend of lower PPI rates are
observed in several newer generation self-expanding THVs
(e.g., Evolut R/PRO 17–18%),16,26,27 the study of Toggweiler et al has
reported in a large series of patients with the NEO valve the lowest
pacemaker rate that has ever been published after TAVI, that is,
2.5%.7 In that study, pre-dilation and post-dilation were performed
with a smaller balloon than the perimeter-derived annular diameter to
F IGURE 2 Clinical outcomes at
6 months. *Patients with pacemaker
at baseline were excluded
F IGURE 3 Adjusted Kaplan–Meier survival analysis, compared
between both devices. Dashed line is unadjusted Kaplan–Meier
[Color figure can be viewed at wileyonlinelibrary.com]
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minimize trauma. Furthermore, the low PPI rate of this NEO valve
might be explained by the top-down implantation with less LVOT
interaction and the lower radial force on the conduction system.
Other studies of the NEO valve have reported slightly higher PPI rates
ranging between 8 and 13%, however, these percentages are still very
encouraging and lowest compared to all other TAVI valves.5-17
4.2 | Device success
Our study showed a comparable device success rate for both studied
valves, which was similar to previous reports (82.4–95.6%).10-14,25,28
These results might argue against the “traditional” perception of the
lower device success rate of the earlier-generation self-expanding
(77.5%) compared to the balloon-expandable (95.9%) THVs.2 The
lower device success in the past was mainly caused by the higher inci-
dence of residual moderate or severe aortic regurgitation after proce-
dure. In our study, we found a low rate of moderate or severe PVL of
1.3%, which was similar between both valve types, and which is in line
with most studies.5-15 Remarkably, the only randomized trial per-
formed, that is, SCOPE I, reported a significantly higher rate of moder-
ate or severe PVL for the NEO valve compared to the S3 (9 vs. 3%).17
Since device success is related to anatomical characteristics of the
aortic complex (degree and pattern of annulus calcification) which
were not taken into account in the IPTW adjustment, the device suc-
cess rate might have been influenced by selection bias (based on
operators experience in device choice) in the present retrospective
study. Nevertheless, the low moderate or severe PVL rates of NEO in
most of the studies are encouraging, since residual moderate/severe
PVL after TAVI has been associated with higher rate of mortality and
therefore motivated the development of internal skirts and external
cuffs to reduce PVL by sealing the prosthesis to the aortic annulus.29
4.3 | Thirty-days outcome
In the present study, the rates of freedom from the early safety com-
posite endpoint were comparable for both valves, without any differ-
ences in the individual contributors to the early safety composite
endpoint. This finding is in line with the results that were reported
recently by other retrospective studies, which reported an early safety
rate between 86 and 94%.11-13,15 The similar stroke rate between
both valves is noteworthy, since post-dilation rate is higher in the
NEO group which has been previously associated with higher inci-
dence of stroke after TAVI.30 This increased rate of post-dilation is
consistent with previous studies11-15,17 and might be explained by the
higher incidence of significant residual aortic regurgitation after initial
valve implantation. Therefore, we assume that higher rate post-
F IGURE 4 Improvement of the New York Heart Association
(NYHA) functional class after transcatheter aortic valve implantation
(TAVI) [Color figure can be viewed at wileyonlinelibrary.com]
F IGURE 5 Mean aortic gradient (a) and aortic regurgitation
(b) after transcatheter aortic valve implantation (TAVI) [Color figure
can be viewed at wileyonlinelibrary.com]
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dilatation with NEO did not affect the clinical outcome negatively
compared to S3.
4.4 | Six-months outcome
We found comparable clinical event rates at 6 months in both THVs.
Even NYHA improvement was similar between both valves. However,
intuitive to the lower radial strength of the NEO,15 a relatively higher
rate of mild PVL with NEO was observed in our study shortly after
TAVI. This finding was also reported by Mauri et al and Barth
et al.13,15 In the SCOPE I study, a similar rate of mild PVL was
reported, with a higher rate of moderate or severe PVL of 9%.17 At
6 months, the rate of mild PVL was in our study almost reduced with
50% between discharge and 6 months post-TAVI in the NEO group
resulting in a comparable rate of PVL in both THVs. The mechanism
of the reduction of PVL might be explained by the possibility of the
self-expanding valve to further expand after initial implant in combina-
tion with occupation of residual interstices by fibrous tissue.31
Furthermore, with both THVs a normal mean aortic gradient is
obtained after TAVI. However, this gradient was significantly lower in
the NEO group compared to S3 up to 6 months of follow-up. These
findings are in line with previous comparative studies.11-15 Mean gra-
dients might influence long-term durability and clinical performance,
however data are limited.32 Thus, the impact of the lower mean gradi-
ent of NEO has yet to be determined by longer-term of follow-up.
4.5 | Clinical implication
This study included all patients with a native tricuspid aortic stenosis
that received a S3 or NEO via transfemoral approach based on the
local experience and preference of the local heart team. Unfortu-
nately, because of the retrospective nature of the study design, the
findings are subject to certain selection bias by the heart team based
on patient and valve specific features and we could not adjust for all
unknown or known selection bias, such as extent of valve calcifica-
tion. For example, the specific technological features of the NEO may
be preferable to S3 in specific patients and vice versa; patients with a
higher risk for annulus rupture due to a small aortic annulus or
patients with an increased risk of PPI might have advantage of the
reduced radial force at the level of LVOT of the NEO valve.10,15
On the other hand, patients with extensive valve calcification
might preferably receive a S3 valve to reduce the risk for incomplete
stent expansion for which post-dilatation is required. Previous studies
have been reporting comparisons between the NEO and S3 as well.
However, these studies consisted of different study populations
(e.g., both transfemoral and transapical approach) or a specific patient
group such as only small annulus. Therefore, the results of these stud-
ies might be biased by for example approach type or not applicable to
all patients. Observational registries are the only way to capture all-
comers data. By using the IPTW method instead of for example, pro-
pensity score matching, no patients had to be excluded, resulting in a
comparison between NEO and S3 reflecting “real-world” clinical out-
comes. The NEO valve might be especially of interest in low risk and
younger patients in which due to the consequences of long-term right
ventricular pacing a PPI is preferably avoided.33 However, recent
results of the SCOPE I trial reported that NEO did not meet non-
inferiority compared with S3 with respect to a composite safety and
efficacy endpoint at 30 days, driven primarily by lower rates of AKI,
and moderate or severe aortic PVL in TAVI patients treated with S3.17
The disparate findings between SCOPE I and our study might be cau-
sed by the fact that none of our patients developed AKI stage 2 or
3 compared to 3.0% in the NEO group of the SCOPE I study. The
authors of SCOPE I reported the following possible explanations for
this increased rate of AKI; the longer mean procedure time, the higher
frequencies of pre- and post-dilation and the higher mean contrast
volume used with NEO valve implantation. Similar trends of these fac-
tors were observed In the present study, however, did not result in an
increase of AKI in the NEO group despite a significant higher mean
contrast volume used. Therefore, other factors contributing to the
rate of AKI should be investigated as well. For example, the differ-
ences in AKI rate between our studies could be due to the different
protocols between centers used for the prevention of contrast-
induced AKI.
A potential factor contributing to the greater PVL rate in the NEO
group in the SCOPE I trial (9.4%) compared to our study (1.4%)
include the difference in pre-dilation rate of these NEO patients. Pre-
dilation ensures optimal valve expansion (by reducing radial counter-
forces) and thereby reducing paravalvular regurgitation. In our study
pre-dilation (with balloon size based on minimum annulus diameter)
was performed in almost all NEO patients (97.4%) compared to 88%
in SCOPE I.
The disparate findings underline the need for future comparison
studies including other new-generation devices, to demonstrate
strengths and limitations of available valve devices and to enable an
optimized patient-tailored device selection.
To note, a novel next-generation ACURATE neo2 valve has been
designed, which will receive CE approval shortly. A new feature of this
new device is the annular sealing technology, which was designed to
further reduce occurrences of PVL. Results demonstrated a high pro-
cedural success rate (97.5%) and a low rate of PVL (3% had moderate
PVL and no cases of more than moderate PVL) at 30-days and one-
year follow-up.34,35 Since most of the features of the first ACURATE
neo valve have been maintained in this new device, we would expect
that the results of the present study would be broadly the same if the
study was performed with the novel ACURATE neo2 system. In terms
of PVL, this novel device might even give a superior outcome com-
pared to the first-generation NEO valve.
4.6 | Limitations
Main limitation of this study is the nonrandomized retrospective
design with the lack of an independent core-laboratory analysis of the
echocardiographic results. In nonrandomized retrospective studies
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propensity score analysis is a well-accepted approach in addressing
imbalance in baseline characteristics after the lack of random alloca-
tion. However, when not all influential baseline characteristics are
taken into account in this analysis, for example, the extent of valve
calcification, correction cannot be made for all selection bias and the
results might have been biased by these (hidden) confounders.
5 | CONCLUSION
In this IPTW, two-center, retrospective study, we found a comparable
result with NEO and S3 regarding device success and early safety
composite endpoint at 30 days according to VARC-2 criteria. Use of
NEO might be associated with a higher incidence of mild PVL com-
pared with S3. However, at medium-term follow up the prevalence of
PVL became similar in both THVs in the presence of a lower mean
aortic gradient in NEO. Up to 6-months follow-up clinical outcomes
remained excellent and comparable.
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